ISDA

Entry Detail

PDB ID:

7YC9

Keywords:

ANTITUMOR PROTEIN

Title:

Co-crystal structure of BTK kinase domain with inhibitor

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Spodoptera frugiperda

PDB Version:

Deposition Date:

2022-07-01

Release Date:

2023-05-17

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.40 Å

R-Value Free:

0.18

R-Value Work:

0.16

R-Value Observed:

0.16

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Tyrosine-protein kinase BTK
Chain IDs:A
Chain Length:269
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:Q06187 Pfam ID:PF07714 EC:2.7.10.2

Ligand Molecules

EDO

IS4

Primary Citation

Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases.

Guo, Y, Hu, N, Liu, Y, Zhang, W, Yu, D, Shi, G, Zhang, B, Yin, L, Wei, M, Yuan, X, Luo, L, Wang, F, Song, X, Xin, L, Wei, Q, Li, Y, Guo, Y, Chen, S, Zhang, T, Zhang, S, Zhou, X, Zhang, C, Su, D, Liu, J, Cheng, Z, Zhang, J, Xing, H, Sun, H, Li, X, Zhao, Y, He, M, Wu, Y, Guo, Y, Sun, X, Tian, A, Zhou, C, Young, S, Liu, X, Wang, L, Wang, Z.Show

J.Med.Chem. 66 4025 4044 (2023)

PMID: 36912866 DOI: 10.1021/acs.jmedchem.2c01938

Abstact

Bruton's tyrosine kinase (BTK) plays an essential role in B-cell receptor (BCR)-mediated signaling as well as the downstream signaling pathway for Fc receptors (FcRs). Targeting BTK for B-cell malignancies by interfering with BCR signaling has been clinically validated by some covalent inhibitors, but suboptimal kinase selectivity may lead to some adverse effects, which also makes the clinical development of autoimmune disease therapy more challenging. The structure-activity relationship (SAR) starting from zanubrutinib (BGB-3111) leads to a series of highly selective BTK inhibitors, in which BGB-8035 is located in the ATP binding pocket and has similar hinge binding to ATP but exhibits high selectivity over other kinases (EGFR, Tec, etc.). With an excellent pharmacokinetic profile as well as demonstrated efficacy studies in oncology and autoimmune disease models, BGB-8035 has been declared a preclinical candidate. However, BGB-8035 showed an inferior toxicity profile compared to that of BGB-3111.

Legend

Protein

Chemical

Disease

Primary Citation of related structures